[go: up one dir, main page]

CA3039596A1 - Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies - Google Patents

Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies Download PDF

Info

Publication number
CA3039596A1
CA3039596A1 CA3039596A CA3039596A CA3039596A1 CA 3039596 A1 CA3039596 A1 CA 3039596A1 CA 3039596 A CA3039596 A CA 3039596A CA 3039596 A CA3039596 A CA 3039596A CA 3039596 A1 CA3039596 A1 CA 3039596A1
Authority
CA
Canada
Prior art keywords
lysophosphatidylcholine
cardiac
dmpc
dmpg
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3039596A
Other languages
English (en)
Other versions
CA3039596C (fr
Inventor
Lawrence Helson
George M. Shopp
Annie Bouchard
Muhammed Majeed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/297,901 external-priority patent/US10449193B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of CA3039596A1 publication Critical patent/CA3039596A1/fr
Application granted granted Critical
Publication of CA3039596C publication Critical patent/CA3039596C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3039596A 2016-10-19 2017-10-19 Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies Active CA3039596C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/297,901 US10449193B2 (en) 2011-06-03 2016-10-19 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US15/297,901 2016-10-19
PCT/US2017/057446 WO2018075801A1 (fr) 2016-10-19 2017-10-19 Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies

Publications (2)

Publication Number Publication Date
CA3039596A1 true CA3039596A1 (fr) 2018-04-26
CA3039596C CA3039596C (fr) 2022-04-12

Family

ID=62019674

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039596A Active CA3039596C (fr) 2016-10-19 2017-10-19 Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies

Country Status (8)

Country Link
EP (1) EP3528848A4 (fr)
JP (1) JP2019531309A (fr)
KR (1) KR20190042775A (fr)
CN (2) CN111481508A (fr)
AU (2) AU2017345473A1 (fr)
CA (1) CA3039596C (fr)
MX (1) MX2019004222A (fr)
WO (1) WO2018075801A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (fr) 2017-01-17 2018-07-26 Heparegenix Gmbh Inhibiteurs de protéine kinase pour favoriser la régénération du foie, ou pour réduire ou prévenir la mort des hépatocytes
KR20240145085A (ko) * 2017-10-19 2024-10-04 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물에 대한 DMPC, DMPG, DMPC/DMPG, LysoPG 및 LysoPC의 보호 효과

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050233970A1 (en) * 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
WO2008093848A1 (fr) * 2007-02-02 2008-08-07 Sunstar Inc. Composition pour diminuer un marqueur d'inflammation comprenant la phosphatidylcholine
JP5638204B2 (ja) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 経口投与用リポソーム製剤およびその製造方法
CA2834968C (fr) * 2011-01-05 2018-01-09 Livon Laboratories Procedes de fabrication de liposomes, compositions a base de liposomes preparees en utilisant les procedes, et procedes d'utilisation associes
EP2714011B1 (fr) * 2011-06-03 2018-01-31 Signpath Pharma Inc. Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
JP2015510514A (ja) * 2012-02-16 2015-04-09 バスキュラー バイオジェニックス リミテッド 乾癬および血管炎症を処置するための方法
WO2014036534A1 (fr) * 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumine-er, nanocurcumine liposomale à liberation prolongée-plga pour réduire au minimum la prolongation du qt dans les thérapies anticancéreuses
EP3151837B1 (fr) * 2014-06-03 2023-03-15 Signpath Pharma, Inc. Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies

Also Published As

Publication number Publication date
CA3039596C (fr) 2022-04-12
AU2017345473A1 (en) 2019-04-18
CN111481508A (zh) 2020-08-04
EP3528848A1 (fr) 2019-08-28
KR20190042775A (ko) 2019-04-24
EP3528848A4 (fr) 2020-07-15
AU2020267307A1 (en) 2020-12-10
CN109843331A (zh) 2019-06-04
JP2019531309A (ja) 2019-10-31
WO2018075801A1 (fr) 2018-04-26
MX2019004222A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
US10238602B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
AU2020286267B2 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
US20190388422A1 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
AU2020267307A1 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
EP3697386B1 (fr) Compositions liquides pour l'usage péroral comprennant dérivés de phosphatidylglycerol et excipients thixotropiques pour le traitement de canalopaties cardiaques causeés par agents pharmacologiques
HK40096187A (en) Liquid compositions for peroral use comprising phosphatidylglycerol derivatives and thixotropic excipients for treating cardiac channelopathies caused by pharmacological agents
HK40033030A (en) Protective compositions and methods against drugs that cause channelopathies
HK40008178A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
HK1241739A1 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
HK1236110B (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
HK1236110A1 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190404